CA3059256C - Covalent small molecule dcn1 inhibitors and therapeutic methods using the same - Google Patents
Covalent small molecule dcn1 inhibitors and therapeutic methods using the same Download PDFInfo
- Publication number
- CA3059256C CA3059256C CA3059256A CA3059256A CA3059256C CA 3059256 C CA3059256 C CA 3059256C CA 3059256 A CA3059256 A CA 3059256A CA 3059256 A CA3059256 A CA 3059256A CA 3059256 C CA3059256 C CA 3059256C
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- date
- substituted
- compound
- date received
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762483640P | 2017-04-10 | 2017-04-10 | |
| US62/483,640 | 2017-04-10 | ||
| PCT/US2018/026789 WO2018191199A1 (en) | 2017-04-10 | 2018-04-10 | Covalent small molecule dcn1 inhibitors and therapeutic methods using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3059256A1 CA3059256A1 (en) | 2018-10-18 |
| CA3059256C true CA3059256C (en) | 2024-04-16 |
Family
ID=62067873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3059256A Active CA3059256C (en) | 2017-04-10 | 2018-04-10 | Covalent small molecule dcn1 inhibitors and therapeutic methods using the same |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10500194B2 (https=) |
| EP (1) | EP3609876B1 (https=) |
| JP (1) | JP7086171B2 (https=) |
| CN (1) | CN110740996B (https=) |
| AU (1) | AU2018251687B2 (https=) |
| CA (1) | CA3059256C (https=) |
| ES (1) | ES2916449T3 (https=) |
| WO (1) | WO2018191199A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| EP3454862B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| EP4491236A3 (en) | 2016-05-10 | 2025-04-02 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| EP4717317A2 (en) | 2017-06-20 | 2026-04-01 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| CN118108706A (zh) | 2017-09-04 | 2024-05-31 | C4医药公司 | 戊二酰亚胺 |
| CN118206529A (zh) | 2017-09-04 | 2024-06-18 | C4医药公司 | 二氢苯并咪唑酮 |
| CN111278816B (zh) | 2017-09-04 | 2024-03-15 | C4医药公司 | 二氢喹啉酮 |
| EP3710002A4 (en) | 2017-11-16 | 2021-07-07 | C4 Therapeutics, Inc. | DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION |
| JP2021519337A (ja) | 2018-03-26 | 2021-08-10 | シー４ セラピューティクス， インコーポレイテッド | Ｉｋａｒｏｓの分解のためのセレブロン結合剤 |
| CN119751456A (zh) | 2018-04-16 | 2025-04-04 | C4医药公司 | 螺环化合物 |
| US20220017908A1 (en) * | 2018-11-20 | 2022-01-20 | Fulcrum Therapeutics, Inc. | Compositions and methods for increasing fetal hemoglobin and treating sickle cell disease |
| CN120698983A (zh) | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
| WO2020181232A1 (en) | 2019-03-06 | 2020-09-10 | C4 Therapeutics, Inc. | Heterocyclic compounds for medical treatment |
| CA3133751A1 (en) | 2019-03-15 | 2020-09-24 | Fulcrum Therapeutics, Inc. | Macrocyclic azolopyridine derivatives as eed and prc2 modulators |
| WO2022125774A1 (en) * | 2020-12-10 | 2022-06-16 | Adgero Biopharmaceuticals Holdings, Inc. | Methods for treating cutaneous metastatic cancers |
| CN112830957B (zh) * | 2021-01-07 | 2022-07-22 | 江西师范大学 | 一种制备卡非佐米的方法 |
| WO2023059605A1 (en) * | 2021-10-04 | 2023-04-13 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and their use in treating disease |
| WO2023059582A1 (en) * | 2021-10-04 | 2023-04-13 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and their use in treating disease |
| JP2025523393A (ja) | 2022-06-06 | 2025-07-23 | シーフォー セラピューティクス， インコーポレイテッド | 二環式置換グルタルイミドセレブロンバインダー |
| CN116987062A (zh) * | 2023-08-03 | 2023-11-03 | 中国热带农业科学院分析测试中心 | 一种氨基酸键联槟榔碱衍生物的制备方法 |
| WO2025096981A1 (en) | 2023-11-03 | 2025-05-08 | Cellarity, Inc. | Modulators of dcn-1 and methods of use thereof |
| US12473285B2 (en) | 2023-11-03 | 2025-11-18 | Cellarity, Inc. | DCN-1 modulating compounds and methods of use thereof |
| TW202543650A (zh) | 2024-03-08 | 2025-11-16 | 美商海爾達醫療運營公司 | 異雙官能化合物及其在治療疾病中之用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ234264A (en) * | 1989-06-29 | 1993-05-26 | Warner Lambert Co | N-substituted cycloalkyl and polycycloalkyl alpha-substituted trp-phe- and phenethylamine derivatives, and pharmaceutical compositions |
| CA2998753A1 (en) * | 2015-09-18 | 2017-03-23 | St. Jude Children's Research Hospital | Methods and compositions of inhibiting dcn1-ubc12 interaction |
-
2018
- 2018-04-10 CN CN201880038225.2A patent/CN110740996B/zh active Active
- 2018-04-10 US US15/949,799 patent/US10500194B2/en active Active
- 2018-04-10 WO PCT/US2018/026789 patent/WO2018191199A1/en not_active Ceased
- 2018-04-10 EP EP18720910.1A patent/EP3609876B1/en active Active
- 2018-04-10 ES ES18720910T patent/ES2916449T3/es active Active
- 2018-04-10 CA CA3059256A patent/CA3059256C/en active Active
- 2018-04-10 JP JP2020504290A patent/JP7086171B2/ja active Active
- 2018-04-10 AU AU2018251687A patent/AU2018251687B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2916449T3 (es) | 2022-07-01 |
| CN110740996A (zh) | 2020-01-31 |
| US20180289677A1 (en) | 2018-10-11 |
| JP2020516679A (ja) | 2020-06-11 |
| CN110740996B (zh) | 2024-01-09 |
| AU2018251687A1 (en) | 2019-10-24 |
| CA3059256A1 (en) | 2018-10-18 |
| EP3609876A1 (en) | 2020-02-19 |
| AU2018251687B2 (en) | 2021-07-29 |
| WO2018191199A1 (en) | 2018-10-18 |
| EP3609876B1 (en) | 2022-03-30 |
| US10500194B2 (en) | 2019-12-10 |
| JP7086171B2 (ja) | 2022-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3059256C (en) | Covalent small molecule dcn1 inhibitors and therapeutic methods using the same | |
| US12012467B2 (en) | Small molecule DCN1 inhibitors and therapeutic methods using the same | |
| AU2022221493B2 (en) | Nitrile-containing antiviral compounds | |
| AU2021253796B2 (en) | Compounds and methods for the treatment of COVID-19 | |
| CA2882496C (en) | Bivalent inhibitors of iap proteins and therapeutic methods using the same | |
| CA3189027A1 (en) | Antiviral heteroaryl ketone derivatives | |
| JP7719250B2 (ja) | 治療用化合物 | |
| EA019008B1 (ru) | Макроциклические производные индола, пригодные в качестве ингибиторов вируса гепатита с | |
| BR112019018688A2 (pt) | derivados de imidazo[4,5-c] quinolina como inibidores de lrrk2 | |
| US20230099018A1 (en) | Hepatitis c virus ns3/4a protease inhibitors | |
| RU2845865C2 (ru) | Нитрилсодержащие противовирусные соединения | |
| EA047572B1 (ru) | Нитрилсодержащие противовирусные соединения | |
| WO2025255442A1 (en) | Trim21-targeted compounds and uses thereof | |
| OA20440A (en) | Nitrile-containing antiviral compounds | |
| WO2013055771A1 (en) | Thioxothiazolidinone derivatives useful as inhibitors of tdp1 | |
| NZ787942A (en) | Nitrile-containing antiviral compounds | |
| OA21481A (en) | Nitrile-containing antiviral compounds. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230406 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250331 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250331 |